Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 8/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.38 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8279463 | 0.77 | RIPK1 (0.37) | MTNR1ARIPK1KMT2A | |
| SCHEMBL28109729 | 0.76 | HTR2A (0.46) | MTNR1AHTR2AHTR2CHTR2BHDAC1 | |
| SCHEMBL8278632 | 0.75 | MTNR1A (0.55) | MTNR1AKMT2ASMN1; SMN2 | |
| SCHEMBL8277210 | 0.73 | ADORA3 (0.37) | MTNR1AKMT2ACHIA | |
| SCHEMBL8279468 | 0.72 | KMT2A (0.35) | MTNR1AHDAC1HDAC6KMT2AHDAC8 | |
| SCHEMBL8279464 | 0.72 | RIPK1 (0.41) | MTNR1ARIPK1KMT2A | |
| SCHEMBL13078126 | 0.71 | ADRA2A (0.40) | MTNR1AHTR2AHTR2CHTR2BKMT2A | |
| SCHEMBL8279302 | 0.71 | HTR2A (0.41) | MTNR1AHTR2AHTR2CHTR2BRIPK1 | |
| SCHEMBL11983384 | 0.69 | FNTA (0.40) | MTNR1AHDAC1HDAC6RIPK1 | |
| SCHEMBL21515929 | 0.69 | NOTUM (0.47) | MTNR1AHDAC1KMT2AHDAC3HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140031277-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031277-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-30 | — | — | US | disclosed |
| US-8536136-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536136-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-17 | — | — | US | disclosed |
| EP-1692157-B1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMA (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-2468744-A2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-27 | — | — | EP | disclosed |
| US-8039623-B2 | Peptidomimetics compound; viricides; interference in life cycle og hepatitis c virus | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039623-B2 | Peptidomimetics compound; viricides; interference in life cycle og hepatitis c virus | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-18 | — | — | US | disclosed |
| EP-2361925-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-31 | — | — | EP | disclosed |
| EP-2311851-A2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-20 | — | — | EP | disclosed |
| US-20070292933-A1 | Inhibitors of serine proteases, particular HCV NS3-NS4A protease | PITLIK JANOS | 2007-12-20 | — | — | US | disclosed |
| US-20070292933-A1 | Inhibitors of serine proteases, particular HCV NS3-NS4A protease | PITLIK JANOS | 2007-12-20 | — | — | US | disclosed |
| US-7273885-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-25 | — | — | US | disclosed |
| US-7273885-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-25 | — | — | US | disclosed |
| US-20070161789-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-12 | — | — | US | disclosed |
| US-20070161789-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-12 | — | — | US | disclosed |
| US-7208600-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208600-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-04-24 | — | — | US | disclosed |
| WO-2005077969-A2 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-08-25 | — | — | WO | disclosed |
| WO-2005037860-A2 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCOPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070292933-A1 | Inhibitors of serine proteases, particular HCV NS3-NS4A protease | SERPINB1, PRSS1, SPINT2 | MTNR1A 3959/4885HTR2A 3297/4885HTR2C 2767/4885 |
| US-20140031277-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | PRSS1, SERPINB1, SPINT2 | MTNR1A 3975/4885HTR2A 3996/4885HTR2C 3519/4885 |
| US-20070161789-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | PRSS1, SERPINB1, SPINT2 | MTNR1A 3975/4885HTR2A 3996/4885HTR2C 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.